Should You Buy Organon & Co. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Organon & Co. (OGN) occupies a solid middle-ground position with a Quality of Company score of 7.3/10. At the current market price of $13.66, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 6 of 10 CirclFi valuation models project upside for Organon & Co. (OGN) at $13.66 — the model consensus leans bullish, with a Quality Score of 7.3/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Organon & Co. (OGN) in 2026?
What Is the Bull Case vs the Bear Case for Organon & Co. (OGN)?
| Bull case — $68.76 target (+403.3%) | Bear case — $0.44 target (-96.8%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Organon & Co.'s rating of 7.3/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model sees the stock as overvalued with a fair value of $0.44 (-96.8%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, 6 of 10 models identify upside from $13.66 to a median fair value of $18.53, indicating the market hasn't fully priced in Organon & Co.'s earnings power. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +500.1% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $68.76 (+403.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | Industry headwind: clinical trial failure represents a meaningful risk for Organon & Co. and its Drug Manufacturers - General peers. |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for Organon & Co.'s revenue and margin trajectory in the Drug Manufacturers - General space. |
How Does OGN Compare to Its Drug Manufacturers - General Peers?
Valuation data pages: PFE · GRFS · SNY · AMRN · ABBV · SCLX · MDCX · LLY · BMY · GILD · MRK
Which Other Stocks Score Like OGN on Quality?
Closest companies to OGN’s Quality of Company score of 7.3/10, across all industries.
- BRZE — Braze, Inc. (QOC 7.3) · analysis
- CPRI — Capri Holdings Limited (QOC 7.3) · analysis
- NSIT — Insight Enterprises, Inc. (QOC 7.3) · analysis
- TG — Tredegar Corporation (QOC 7.3) · analysis
- KWR — Quaker Chemical Corporation (QOC 7.3) · analysis
- CWST — Casella Waste Systems, Inc. (QOC 7.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Organon & Co. (OGN) Worth Buying in 2026?
Organon & Co. leans positive in our analysis — 6/10 models bullish, median fair value of $18.53 vs. $13.66, QOC 7.3/10. The case is constructive but not overwhelming, and the 4 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Organon & Co.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About OGN Stock?
Should I buy OGN stock right now?
Based on CirclFi's multi-model analysis, 6 of 10 models see upside for OGN at $13.66. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Organon & Co.?
Key risks include: wide model disagreement (15596% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does OGN compare to its competitors?
Among Drug Manufacturers - General peers, OGN holds a Quality Score of 7.3/10. Comparable companies include PFE (QOC 7.5), GRFS (QOC 6.9), SNY (QOC 7.6). The relative ranking helps investors identify whether OGN offers better fundamental quality than alternatives in the same sector.
Is OGN a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. OGN's Quality Score of 7.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy OGN at?
CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $0.44 to $68.76. At $13.66, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for OGN.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad